Soligenix Q1 net loss narrows on lower expenses

Soligenix

08/05/2026 12:39

Overview

US biopharma firm's Q1 net loss narrowed due to lower operating expenses

Company reported no revenue for Q1 2026

Phase 3 FLASH2 trial for HyBryte in CTCL halted for futility after interim analysis

Outlook

Company is analyzing FLASH2 trial data and may explore further regulatory discussions if warranted

Soligenix evaluating all strategic options, including M&A and advancing pipeline assets

Company has cash runway into Q2 2027 and is assessing future development priorities

Result Drivers

TRIAL HALT - Interim analysis led to halt of Phase 3 FLASH2 trial for HyBryte in CTCL due to futility

LOWER OPERATING EXPENSES - Net loss narrowed mainly due to decreased third-party manufacturing costs, completion of Phase 2 BD study, and lower site initiation fees, partly offset by higher patient fees for Phase 3 CTCL trial

Company press release: ID:nPnxlhT2a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$2.8 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Soligenix Inc is $6.00, about 1,846.8% above its May 7 closing price of $0.31

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)